QUOTED. Jayson Bedford.
Results from Medtronic’s pivotal SPYRAL HTN-ON MED trial of its Symplicity renal denervation system have been delayed until next year. Analyst Jayson Bedford of Raymond James Financial says the move may dent investor confidence.
“While the [renal denervation] opportunity is not lost, confidence in the program has now been dented.” – Jayson Bedford, analyst, Raymond James Financial
Click here for a free trial of Medtech Insight